The growing prevalence of polycythemia vera among people and other major driving factors is expected to favor the rise in the global polycythemia vera interferon therapeutics market
Reports and Insights has published a new report titled, “Polycythemia Vera Interferon Therapeutics Market: Opportunity Analysis and Future Assessment 2020-2028”
Global Polycythemia Vera Interferon Therapeutics Market, By Interferon Type (Interferon Alpha 2a, Interferon Alpha 2b, Pegylated interferon (Controlled Release, Sustained Release)), By Dosage (1 mL Vial, 0.5 mL Prefilled Syringe, 0.5 mL Disposable Auto injector), By Route of Administration (Subcutaneous Injection, Intramuscular Injection), By DIstribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2020 and 2028.
The global polycythemia vera interferon therapeutics market in 2020 is estimated for more than US$ xx Bn and expected to reach a value of US$ xx Bn by 2028 with a significant CAGR of xx%.
Polycythemia vera can be perceived as a distinct and a chronic blood disorder involving the production of excessive amounts of blood cells in the bone marrow. The overabundance of red blood cells is most tragic, but the generation of platelets and white blood cells are also exalted in several cases. Given that red blood cells are produced in excessive amounts in the marrow, this paves its way to unusually higher numbers of prevailing red blood cells (red blood mass) within the blood. For this reason, the blood stiffens and grows in volume, a condition commonly known as hyperviscosity. The thicker blood than normal is not likely to flow through tinier blood vessels appropriately.
A range of symptoms can happen in individuals suffering with polycythemia vera comprising unspecific symptoms such as headaches, weakness, fatigue, itchy skin or dizziness, an extended spleen (splenomegaly), a range of gastrointestinal disorders, and the risk of formation of blood clots, which further leads to restrict blood flow to essential organs.
However, the interferon alpha is a drug obtained from human cells that regulates the immune system, combats various infections, and comprise anti-tumor activity. The interferon therapeutics is considered effective for the treatment of polycythemia vera. Though it is still a second-line drug for this condition, interferon therapeutics is believed to be one of the therapies that is proven significantly successful that has the potential to prevent the development of abnormal cells and improve the actions of white cells that may strike and kill tumor cells. Attributing to which, the global polycythemia vera interferon therapeutics market is expected to witness significant demand in the forthcoming years.
In addition to that, the growing prevalence of polycythemia vera among the population worldwide is further playing a major role in thrusting the market growth in the coming years.